Table 1:

Patient and tumor characteristics

Total CohortEmboNo EmboP Value
Total patients470174307
Total treated meningiomas504177327
Mean age (range) (yr)57 (17–90)56 (17–82)58 (18–90).2988
Female (%)336 (71.5)116 (66.7)223 (72.6).185
Tumor location<.001a
    Olfactory groove (%)27 (5.5)5 (2.9)22 (6.9)
    Planum sphenoidale/tuberculum (%)42 (8.6)5 (2.9)37 (11.6)
    Cavernous sinus (%)5 (1.0)05 (1.6)
    Sphenoid wing (%)66 (13.5)31 (18.0)35 (11.0)
    Suprasellar (%)2 (0.4)02 (0.6)
    Convexity (%)187 (38.2)65 (37.8)122 (38.2)
    Parasagittal (%)88 (18.0)41 (23.8)47 (14.7)
    Middle cranial fossa (%)12 (2.4)2 (1.2)10 (3.1)
    Posterior fossa (%)41 (8.4)18 (10.5)24 (7.5)
    Intraosseous (%)1 (0.2)1 (0.6)0
    Intraventricular (%)9 (1.8)09 (2.8)
    Cerebellopontine angle (%)10 (2.0)4 (2.3)6 (1.9)
Skull base location (%)164 (33.4)47 (27.3)117 (36.7).036a
Max. tumor diameter (mm) (range)38.7 (5–89)45.6 (16–89)34.9 (5–89)<.001a
Prior resection (%)59 (11.9)11 (6.4)48 (15.0).005a
Prior radiosurgery (%)35 (7.0)11 (6.3)24 (7.5).626
Prior radiotherapy (%)12 (2.4)5 (2.9)7 (2.2).633
WHO grade.807
    I344 (74.8)121 (75.2)223 (74.6)
    II98 (21.3)35 (21.7)63 (21.1)
    III18 (3.9)5 (3.1)13 (4.3)
Brain invasion108 (21.4)42 (23.7)56 (17.1).773
  • Note:—Embo indicates embolized group; –, not significant; No Embo, non-embolized group; Max., maximum; WHO, World Health Organization.

  • a Significant difference.